PACAP (6-38), HUMAN, OVINE, RAT
| 中文名称 | PACAP (6-38), HUMAN, OVINE, RAT |
|---|---|
| 中文同义词 | HUMAN PACAP(6-38);人垂体腺苷酸环化酶激活肽(6-38);PACAP 6-38 TFA,PAC1受体拮抗剂;PAC1受体拮抗剂 |
| 英文名称 | PACAP 6-38 |
| 英文同义词 | H-PHE-THR-ASP-SER-TYR-SER-ARG-TYR-ARG-LYS-GLN-MET-ALA-VAL-LYS-LYS-TYR-LEU-ALA-ALA-VAL-LEU-GLY-LYS-ARG-TYR-LYS-GLN-ARG-VAL-LYS-ASN-LYS-NH2;PITUITARY ADENYLATE CYCLASE ACTIVATING PEPTIDE (6-38), HUMAN, OVINE, RAT;PITUITARY ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE-38 (6-38) (HUMAN, CHICKEN, MOUSE, OVINE, PORCINE, RAT);PITUITARY ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE (6-38) AMIDE (HUMAN, OVINE, RAT);PITUITARY ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE (HUMAN, 6-38) OVINE, RAT;PACAP-38 (6-38) (HUMAN, CHICKEN, MOUSE, OVINE, PORCINE, RAT);PACAP (6-38), AMIDE, HUMAN, OVINE, RAT;PACAP (6-38), HUMAN, OVINE, RAT |
| CAS号 | 143748-18-9 |
| 分子式 | C182H300N56O45S |
| 分子量 | 4024.7426 |
| EINECS号 | |
| 相关类别 | 多肽;标准品;目录肽;Peptide |
| Mol文件 | 143748-18-9.mol |
| 结构式 |  |
PACAP (6-38), HUMAN, OVINE, RAT 性质
| 储存条件 | -15°C |
|---|---|
| 形态 | 固体 |
| 水溶解性 | Soluble to 2 mg/ml in water |
IC50: 30 nM (PACAP type I receptor), 600 nM (PACAP type II receptor VIP 1 ), 40 nM (PACAP type II receptor VIP 2 )
An increase of dopamine (DA) content by HPLC analysis and/or cell proliferation identified by MTT assay by Dexamethasone (DEX) is also observed which can be inhibited by PACAP (6-38) at concentration sufficient to block PACAP type 1 (PAC1) receptor. Pretreatment with PAC1 receptor antagonist PACAP (6-38) at 0.1 or 1 μM for 2 h significantly blocks this increase of DA content by 1 μM DEX. The MTT assay shows that DEX increases cell proliferation. Moreover, this action is also inhibited by the pre-incubation of PACAP (6-38). PACAP (6-38) at 1μM shows no effect on DA content and cell proliferation for 24 h. However, PACAP (6-38) at 0.3 μM has been mentioned to reduce the spontaneous tyrosine hydroxylase (TH) accumulation in differentiated retinal cultured cells for 5 days.
Intravesical administration of the PAC1 receptor antagonist, PACAP (6-38) (300 nM), significantly (p≤0.01) increases intercontraction interval (2.0-fold) and void volume (2.5-fold) in NGF-OE mice. Intravesical instillation of PACAP (6-38) also decreases baseline bladder pressure in NGF-OE mice. Intravesical administration of PACAP (6-38) (300 nM) significantly (p≤0.01) reduces pelvic sensitivity in NGF-OE mice but is without effect in WT mice.